Literature DB >> 9177234

Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains.

Z Lu1, J F Berson, Y Chen, J D Turner, T Zhang, M Sharron, M H Jenks, Z Wang, J Kim, J Rucker, J A Hoxie, S C Peiper, R W Doms.   

Abstract

The chemokine receptor CXCR4 functions as a fusion coreceptor for T cell tropic and dual-tropic HIV-1 strains. To identify regions of CXCR4 that are important for coreceptor function, CXCR4-CXCR2 receptor chimeras were tested for the ability to support HIV-1 envelope (env) protein-mediated membrane fusion. Receptor chimeras containing the first and second extracellular loops of CXCR4 supported fusion by T tropic and dual-tropic HIV-1 and HIV-2 strains and binding of a monoclonal antibody to CXCR4, 12G5, that blocks CXCR4-dependent infection by some virus strains. The second extracellular loop of CXCR4 was sufficient to confer coreceptor function to CXCR2 for most virus strains tested but did not support binding of 12G5. Truncation of the CXCR4 cytoplasmic tail or mutation of a conserved DRY motif in the second intracellular loop did not affect coreceptor function, indicating that phosphorylation of the cytoplasmic tail and the DRY motif are not required for coreceptor function. The results implicate the involvement of multiple CXCR4 domains in HIV-1 coreceptor function, especially the second extracellular loop, though the structural requirements for coreceptor function were somewhat variable for different env proteins. Finally, a hybrid receptor in which the amino terminus of CXCR4 was replaced by that of CCR5 was active as a coreceptor for M tropic, T tropic, and dual-tropic env proteins. We propose that dual tropism may evolve in CCR5-restricted HIV-1 strains through acquisition of the ability to utilize the first and second extracellular loops of CXCR4 while retaining the ability to interact with the CCR5 amino-terminal domain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177234      PMCID: PMC21066          DOI: 10.1073/pnas.94.12.6426

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells.

Authors:  P A Ashorn; E A Berger; B Moss
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.

Authors:  R E Atchison; J Gosling; F S Monteclaro; C Franci; L Digilio; I F Charo; M A Goldsmith
Journal:  Science       Date:  1996-12-13       Impact factor: 47.728

4.  Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus.

Authors:  S Chakrabarti; T Mizukami; G Franchini; B Moss
Journal:  Virology       Date:  1990-09       Impact factor: 3.616

5.  Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus.

Authors:  P R Clapham; D Blanc; R A Weiss
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

6.  Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor.

Authors:  W A Alexander; B Moss; T R Fuerst
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

Authors:  O Nussbaum; C C Broder; E A Berger
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

Review 9.  Sequence alignment of the G-protein coupled receptor superfamily.

Authors:  W C Probst; L A Snyder; D I Schuster; J Brosius; S C Sealfon
Journal:  DNA Cell Biol       Date:  1992 Jan-Feb       Impact factor: 3.311

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  69 in total

1.  CXCR4 is the primary receptor for feline immunodeficiency virus in astrocytes.

Authors:  K Nakagaki; K Nakagaki; K Takahashi; D Schols; E De Clercq; T Tabira
Journal:  J Neurovirol       Date:  2001-10       Impact factor: 2.643

Review 2.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

3.  Critical role in CXCR4 signaling and internalization of the polypeptide main chain in the amino terminus of SDF-1α probed by novel N-methylated synthetically and modularly modified chemokine analogues.

Authors:  Chang-Zhi Dong; Shaomin Tian; Won-Tak Choi; Santhosh Kumar; Dongxiang Liu; Yan Xu; Xiaofeng Han; Ziwei Huang; Jing An
Journal:  Biochemistry       Date:  2012-07-23       Impact factor: 3.162

4.  Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein.

Authors:  R Bron; P J Klasse; D Wilkinson; P R Clapham; A Pelchen-Matthews; C Power; T N Wells; J Kim; S C Peiper; J A Hoxie; M Marsh
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Authors:  Neelanjana Ray; Jessamina E Harrison; Leslie A Blackburn; Jeffrey N Martin; Steven G Deeks; Robert W Doms
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

6.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

7.  Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop.

Authors:  Phanourios Tamamis; Christodoulos A Floudas
Journal:  Biophys J       Date:  2013-09-17       Impact factor: 4.033

8.  Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.

Authors:  Xiaoli Wang; Wei Zhang; Takefumi Ishii; Selcuk Sozer; Jiapeng Wang; Mingjiang Xu; Ronald Hoffman
Journal:  Cancer Res       Date:  2009-09-14       Impact factor: 12.701

Review 9.  Chemokine receptors and chemokines in HIV infection.

Authors:  A Garzino-Demo; A L DeVico; R C Gallo
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

Review 10.  Early events of HIV-1 infection: can signaling be the next therapeutic target?

Authors:  Kate L Jones; Redmond P Smyth; Cândida F Pereira; Paul U Cameron; Sharon R Lewin; Anthony Jaworowski; Johnson Mak
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.